First Time Loading...

HLS Therapeutics Inc
TSX:HLS

Watchlist Manager
HLS Therapeutics Inc Logo
HLS Therapeutics Inc
TSX:HLS
Watchlist
Price: 4.65 CAD Market Closed
Updated: May 3, 2024

Wall Street
Price Targets

HLS Price Targets Summary
HLS Therapeutics Inc

Wall Street analysts forecast HLS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HLS is 6.86 CAD with a low forecast of 4.19 CAD and a high forecast of 11.03 CAD.

Lowest
Price Target
4.19 CAD
10% Downside
Average
Price Target
6.86 CAD
48% Upside
Highest
Price Target
11.03 CAD
137% Upside
HLS Therapeutics Inc Competitors:
Price Targets
4164
CHC Healthcare Group
34% Upside
PGC
Paragon Care Ltd
3% Downside
FAGR
Fagron NV
18% Upside
000705
Zhejiang Zhenyuan Share Co Ltd
98% Upside
7476
As One Corp
45% Upside
EBO
EBOS Group Ltd
12% Upside
NEU
Neuca SA
0% Upside
CAU
Cronos Australia Ltd
178% Upside

Revenue
Forecast

Revenue Estimate
HLS Therapeutics Inc

The compound annual growth rate of HLS Therapeutics Inc's revenue for the next 3 years is 11%.

N/A
Past Growth
11%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
HLS Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
14%
Average Beat

Net Income
Forecast

Net Income Estimate
HLS Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
14%
Average Beat

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HLS's stock price target?
Price Target
6.86 CAD

According to Wall Street analysts, the average 1-year price target for HLS is 6.86 CAD with a low forecast of 4.19 CAD and a high forecast of 11.03 CAD.

What is HLS Therapeutics Inc's Revenue forecast?
Projected CAGR
11%

The compound annual growth rate of HLS Therapeutics Inc's revenue for the next 3 years is 11%.